INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Exclusion Criteria

• •Have received chemotherapy, targeted small molecule therapy or curative radiation within 21 days of first dose of study drug; prior mAB for anticancer therapy other within 28 days of first dose of study drug; or investigational study drugs or devices within 28 days or five half-lives prior to enrollment unless approved by medical monitor.
• •Prior treatment with any TNF Super Family agonist therapy.
• •Have not recovered to ≤ Grade 1 from toxic effects of prior therapy.
• •Laboratory and medical history parameters not within the Protocol-defined range before the first administration of study treatment.
• •Known active HBV or HCV, or Known to be seropositive for HIV.
• •Have an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs).
• •Have an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs).
• •Known active infections requiring systemic treatment.